Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd as indicated in metadata) covers the quarter ended September 30, 2018, filed on October 30, 2018. The registrant is an Australian biotechnology entity subject to ASX Listing Rule 4.7B, reporting its quarterly cash flow activities.
Key Financial Metrics
All figures are in Australian Dollars (A$) in thousands.
| Metric | Current Quarter | Year to Date (3 Months) |
|---|---|---|
| Net Cash from Operating Activities | (3,264) | (3,264) |
| Net Cash from Financing Activities | 159 | 159 |
| Net Increase in Cash and Cash Equivalents | 15,235 | 15,235 |
| Cash and Cash Equivalents (End of Quarter) | 12,277 | 12,277 |
| Proceeds from Share Issues | 166 | 163 |
| Estimated Cash Outflows (Next Quarter) | 4,520 | - |
Operating Expenses Breakdown (Cash Paid):
- Research and Development: $0 (No cash outflow reported in this specific line item)
- Staff Costs: $924
- Administration and Corporate Costs: $306
- Advertising and Marketing: $42
Debt and Liquidity: The filing reports no loan facilities, credit standby arrangements, or borrowings drawn at quarter end. The company holds $7,277 in bank balances and $5,000 in call deposits.
Material Changes
The filing does not provide comparative data for the prior year or prior quarter to calculate percentage changes in revenue or profit, as the company reported no receipts from customers. The primary activity was a net cash outflow from operations of $3,264, partially offset by financing proceeds of $166 from share issues. The significant increase in total cash (from $15,235 at the start of the period to $12,277 at the end, adjusted for exchange rates) reflects the net burn rate against existing reserves.
Guidance, Outlook, and Risks
Outlook: Management estimates total cash outflows for the next quarter to be $4,520, primarily driven by Research and Development ($3,000), Staff Costs ($900), and Administration ($600).
Risks and Contingencies: The filing does not explicitly detail specific risks or contingencies beyond the standard disclosure of cash burn. The company relies on share issuances to fund operations, as evidenced by the $166 proceeds from share issues in the current quarter. There are no reported acquisitions or disposals of business entities.
Investor Verification Checklist
- Company Identity: Verify that the filing pertains to Prana Biotechnology Limited (ASX: PRN), not Alteryx Therapeutics, as the metadata name appears incorrect.
- Revenue Status: Confirm the absence of customer receipts, indicating the company is pre-revenue and reliant on capital raises.
- Cash Runway: Assess the sustainability of the $12,277 cash balance against the estimated $4,520 quarterly burn rate.
- Capital Raising: Monitor the frequency and size of share issues, as this is the primary source of financing.
- Related Party Payments: Note the $241 paid to directors and associates for salaries and fees.